Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab with Gemcitabine, Nab-paclitaxel and Radiotherapy in LAPC
NCT06472037Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2024
- Primary completion
- May 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Jul 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06472037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06472037.